Revenue
2024
2025
20/20 Biolabs, Inc. (AIDX)
Price—Loading quote
Net income
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $2.0M | $1.8M |
| Gross profit | $604,541 | $360,311 |
| Research & development | $592,569 | $1.3M |
| Operating expenses | $3.9M | $6.0M |
| Operating income | −$3.3M | −$5.7M |
| EBITDAderived | −$3.3M | −$5.6M |
| Net income | −$3.7M | −$5.6M |
| Basic EPSper diluted share | -$0.76 | -$1.16 |
| Diluted EPSper diluted share | -$0.76 | -$1.16 |